Cargando…
Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition
To investigate the prevalence of sarcopenia among people living with HIV (PLWH) in Japan and analyze the relationship between HIV infection and ART effects on the body composition of Japanese PLWH for more appropriate drug selection and lifestyle guidance. Cross-sectional observational study. We inc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592382/ https://www.ncbi.nlm.nih.gov/pubmed/36281131 http://dx.doi.org/10.1097/MD.0000000000031349 |
_version_ | 1784814912920354816 |
---|---|
author | Konishi, Keiji Nakagawa, Hidenori Asaoka, Tomohiro Kasamatsu, Yu Goto, Tetsushi Shirano, Michinori |
author_facet | Konishi, Keiji Nakagawa, Hidenori Asaoka, Tomohiro Kasamatsu, Yu Goto, Tetsushi Shirano, Michinori |
author_sort | Konishi, Keiji |
collection | PubMed |
description | To investigate the prevalence of sarcopenia among people living with HIV (PLWH) in Japan and analyze the relationship between HIV infection and ART effects on the body composition of Japanese PLWH for more appropriate drug selection and lifestyle guidance. Cross-sectional observational study. We included male patients aged ≥ 60 years whose body composition was measured by InBody 570 body composition analyzer during outpatient visits. Patients were classified by body shape based on body mass index (BMI) and body fat percentage measurements and by tenofovir alafenamide administration. Hidden obesity is a condition wherein the BMI is within the standard range but the body fat percentage is higher than the reference. Patients with low muscle mass and strength were considered to have sarcopenia, whereas those with only low muscle strength were considered to have pre-sarcopenia. In total, 87 patients were included. Based on body shape determined by BMI and body fat percentage, most patients had hidden obesity (40 patients, 46.0%). Sarcopenia was detected in 9 patients (10.3%) and pre-sarcopenia in 14 patients (16.1%). The tenofovir alafenamide (TAF) use group had significantly higher BMI, higher skeletal muscle mass, body fat mass, and skeletal muscle mass index relative to the non-TAF use group. Hidden obesity is a risk for lifestyle diseases. It is important to recognize it based on body composition measurements because it can be missed by BMI measurement alone. Tenofovir alafenamide therapy increases skeletal muscle mass, which may result in the prevention of sarcopenia. To clarify how TAF affects the development of sarcopenia and lifestyle diseases, future studies on a larger cohort are warranted. |
format | Online Article Text |
id | pubmed-9592382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95923822022-10-25 Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition Konishi, Keiji Nakagawa, Hidenori Asaoka, Tomohiro Kasamatsu, Yu Goto, Tetsushi Shirano, Michinori Medicine (Baltimore) 4850 To investigate the prevalence of sarcopenia among people living with HIV (PLWH) in Japan and analyze the relationship between HIV infection and ART effects on the body composition of Japanese PLWH for more appropriate drug selection and lifestyle guidance. Cross-sectional observational study. We included male patients aged ≥ 60 years whose body composition was measured by InBody 570 body composition analyzer during outpatient visits. Patients were classified by body shape based on body mass index (BMI) and body fat percentage measurements and by tenofovir alafenamide administration. Hidden obesity is a condition wherein the BMI is within the standard range but the body fat percentage is higher than the reference. Patients with low muscle mass and strength were considered to have sarcopenia, whereas those with only low muscle strength were considered to have pre-sarcopenia. In total, 87 patients were included. Based on body shape determined by BMI and body fat percentage, most patients had hidden obesity (40 patients, 46.0%). Sarcopenia was detected in 9 patients (10.3%) and pre-sarcopenia in 14 patients (16.1%). The tenofovir alafenamide (TAF) use group had significantly higher BMI, higher skeletal muscle mass, body fat mass, and skeletal muscle mass index relative to the non-TAF use group. Hidden obesity is a risk for lifestyle diseases. It is important to recognize it based on body composition measurements because it can be missed by BMI measurement alone. Tenofovir alafenamide therapy increases skeletal muscle mass, which may result in the prevention of sarcopenia. To clarify how TAF affects the development of sarcopenia and lifestyle diseases, future studies on a larger cohort are warranted. Lippincott Williams & Wilkins 2022-10-21 /pmc/articles/PMC9592382/ /pubmed/36281131 http://dx.doi.org/10.1097/MD.0000000000031349 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 4850 Konishi, Keiji Nakagawa, Hidenori Asaoka, Tomohiro Kasamatsu, Yu Goto, Tetsushi Shirano, Michinori Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition |
title | Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition |
title_full | Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition |
title_fullStr | Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition |
title_full_unstemmed | Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition |
title_short | Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition |
title_sort | sarcopenia among people living with hiv and the effect of antiretroviral therapy on body composition |
topic | 4850 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592382/ https://www.ncbi.nlm.nih.gov/pubmed/36281131 http://dx.doi.org/10.1097/MD.0000000000031349 |
work_keys_str_mv | AT konishikeiji sarcopeniaamongpeoplelivingwithhivandtheeffectofantiretroviraltherapyonbodycomposition AT nakagawahidenori sarcopeniaamongpeoplelivingwithhivandtheeffectofantiretroviraltherapyonbodycomposition AT asaokatomohiro sarcopeniaamongpeoplelivingwithhivandtheeffectofantiretroviraltherapyonbodycomposition AT kasamatsuyu sarcopeniaamongpeoplelivingwithhivandtheeffectofantiretroviraltherapyonbodycomposition AT gototetsushi sarcopeniaamongpeoplelivingwithhivandtheeffectofantiretroviraltherapyonbodycomposition AT shiranomichinori sarcopeniaamongpeoplelivingwithhivandtheeffectofantiretroviraltherapyonbodycomposition |